Back to Journals » Therapeutics and Clinical Risk Management » Volume 14

Mesenchymal stem cell transplantation as an effective treatment strategy for ischemic stroke in Asia: a meta-analysis of controlled trials

Authors Xue P, Wang M, Yan GH

Received 2 January 2018

Accepted for publication 21 March 2018

Published 14 May 2018 Volume 2018:14 Pages 909—928

DOI https://doi.org/10.2147/TCRM.S161326

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Justinn Cochran

Peer reviewer comments 3

Editor who approved publication: Professor Deyun Wang


Ping Xue, Min Wang, Guanhua Yan

Department of Neurology, Liaocheng People’s Hospital, Liaocheng Clinical School of Taishan Medical University, Liaocheng, People’s Republic of China

Objective: The aim of this study was to evaluate the efficacy and safety of the mesenchymal stem cell (MSC) therapy in patients with ischemic stroke (IS).
Materials and methods: Clinical trials involved in this research were searched from PubMed, Web of Science, Cochrane Library, Embase, Wanfang and CNKI database. Therapeutic effects of MSC therapy were assessed according to National Institutes of Health Stroke Scale (NIHSS), Barthel index (BI), Fugl-Meyer Assessment (FMA) and Functional Independence Measure (FIM), and its safety was evaluated based on adverse events.
Results: This research covered 23 trials including 1,279 IS patients. Based on our analysis, the overall condition of IS patients significantly improved after MSC therapy, indicated by decreased NIHSS and increased BI, FMA and FIM scores. Our analysis also showed that the treatment effects in the MSC transplantation group were superior to those in the control group (routine medication therapy) with statistical significance for NIHSS (1 month after therapy: odds ratio [OR]=-1.92, CI=-3.49 to -0.34, P=0.02; 3 months after therapy: OR=-2.65, CI=-3.40 to -1.90, P<0.00001), BI (1 month after therapy: OR=0.99, CI=0.19–1.79, P=0.02; 6 months after therapy: OR=10.10, CI=3.07–17.14, P=0.005), FMA (3 months after therapy: OR=10.20, CI=3.70–16.70, P=0.002; 6 months after therapy: OR=10.82, CI=6.45–15.18, P<0.00001) and FIM (1 month after therapy: OR=15.61, CI=-0.02 to 31.24, P=0.05; 6 months after therapy: OR=16.56, CI=9.06–24.06, P<0.0001). No serious adverse events were reported during MSC therapy.
Conclusion: MSC therapy is safe and effective in treating IS by improving the neurological deficits, motor function and daily life quality of patients.

Keywords: mesenchymal stem cells, routine medication, ischemic stroke, meta-analysis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]